US 12,285,427 B2
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor
Remi-Martin Laberge, South San Francisco, CA (US); Judith Campisi, Berkeley, CA (US); Marco Demaria, San Francisco, CA (US); Bennett G. Childs, Rochester, MN (US); Jan M. A. Van Deursen, Rochester, MN (US); Nathaniel David, South San Francisco, CA (US); and Alain Philippe Vasserot, South San Francisco, CA (US)
Assigned to Unity Biotechnology, Inc., South San Francisco, CA (US); Mayo Foundation for Medical Education and Research, Rochester, MN (US); and Buck Institute for Research on Aging, Novato, CA (US)
Filed by Buck Institute for Research on Aging, Novato, CA (US); Mayo Foundation for Medical Education and Research, Rochester, MN (US); and Unity Biotechnology, Inc., South San Francisco, CA (US)
Filed on Aug. 7, 2023, as Appl. No. 18/215,731.
Application 18/215,731 is a continuation of application No. 17/548,004, filed on Dec. 10, 2021.
Application 17/548,004 is a continuation of application No. 16/403,389, filed on May 3, 2019, abandoned.
Application 16/403,389 is a continuation in part of application No. 15/950,965, filed on Apr. 11, 2018, granted, now 10,413,542, issued on Sep. 17, 2019.
Application 15/950,965 is a continuation of application No. 15/114,762, granted, now 9,993,472, issued on Jun. 12, 2018, previously published as PCT/US2015/013387, filed on Jan. 28, 2015.
Claims priority of provisional application 62/061,627, filed on Oct. 8, 2014.
Claims priority of provisional application 62/061,629, filed on Oct. 8, 2014.
Claims priority of provisional application 62/057,828, filed on Sep. 30, 2014.
Claims priority of provisional application 62/057,825, filed on Sep. 30, 2014.
Claims priority of provisional application 62/057,820, filed on Sep. 30, 2014.
Claims priority of provisional application 62/044,664, filed on Sep. 2, 2014.
Claims priority of provisional application 62/042,708, filed on Aug. 27, 2014.
Claims priority of provisional application 62/002,709, filed on May 23, 2014.
Claims priority of provisional application 61/979,911, filed on Apr. 15, 2014.
Claims priority of provisional application 61/932,704, filed on Jan. 28, 2014.
Claims priority of provisional application 61/932,711, filed on Jan. 28, 2014.
Prior Publication US 2024/0115563 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 31/404 (2006.01); A61K 31/4178 (2006.01); A61K 31/428 (2006.01); A61K 31/4375 (2006.01); A61K 31/495 (2006.01); A61K 31/5377 (2006.01); A61K 31/728 (2006.01); A61K 45/06 (2006.01); A61K 47/36 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 25/16 (2006.01); A61P 27/02 (2006.01); C12N 5/00 (2006.01); A61P 25/28 (2006.01); C12Q 1/48 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0048 (2013.01); A61K 9/0073 (2013.01); A61K 31/404 (2013.01); A61K 31/4178 (2013.01); A61K 31/428 (2013.01); A61K 31/4375 (2013.01); A61K 31/495 (2013.01); A61K 31/5377 (2013.01); A61K 31/728 (2013.01); A61K 45/06 (2013.01); A61K 47/36 (2013.01); A61P 9/10 (2018.01); A61P 11/00 (2018.01); A61P 25/16 (2018.01); A61P 27/02 (2018.01); C12N 5/0081 (2013.01); A61P 25/28 (2018.01); C12N 2501/999 (2013.01); C12N 2503/02 (2013.01); C12Q 1/485 (2013.01)] 4 Claims
 
1. A method for treating a senescence-associated ocular disease or disorder in an eye of a subject in need thereof, the method comprising administering an inhibitor of a Bcl-2 anti-apoptotic protein family member, wherein the inhibitor is WEHI-539 or A-1155463, and wherein the inhibitor selectively eliminates senescent cells in the eye of the subject.